BACKGROUND: Age-related reductions in serum dehydroepiandrosterone (DHEA) concentrations may be involved in bone mineral density (BMD) losses. OBJECTIVE: The objective was to determine whether DHEA supplementation in older adults improves BMD when co-administered with vitamin D and calcium. DESIGN: In year 1, a randomized trial was conducted in which men (n = 55) and women (n = 58) aged 65-75 y took 50 mg/d oral DHEA supplements orplacebo. In year 2, all participants took open-label DHEA (50 mg/d). During both years, all participants received vitamin D (16 microg/d) and calcium (700 mg/d) supplements. BMD was measured by using dual-energy X-ray absorptiometry. Concentrations of hormones and bone turnover markers were measured in serum. RESULTS: In men, no difference between groups occurred in any BMD measures or in bone turnover markers during year 1 or year 2. The free testosterone index and estradiol increased in the DHEA group only. In women, spine BMD increased by 1.7 +/- 0.6% (P = 0.0003) during year 1 and by 3.6 +/- 0.7% after 2 y of supplementation in the DHEA group; however, in the placebo group, spine BMD was unchanged during year 1 but increased to 2.6 +/- 0.9% above baseline during year 2 after the crossover to DHEA. Hip BMD did not change. Testosterone, estradiol, and insulin-like growth factor 1 increased in the DHEA group only. In both groups, serum concentrations of bone turnover markers decreased during year 1 and remained low during year 2, but did not differ between groups. CONCLUSION:DHEA supplementation in older women, but not in men, improves spine BMD when co-administered with vitamin D and calcium. This trial was registered at clinicaltrials.gov as NCT00182975.
RCT Entities:
BACKGROUND: Age-related reductions in serum dehydroepiandrosterone (DHEA) concentrations may be involved in bone mineral density (BMD) losses. OBJECTIVE: The objective was to determine whether DHEA supplementation in older adults improves BMD when co-administered with vitamin D and calcium. DESIGN: In year 1, a randomized trial was conducted in which men (n = 55) and women (n = 58) aged 65-75 y took 50 mg/d oral DHEA supplements or placebo. In year 2, all participants took open-label DHEA (50 mg/d). During both years, all participants received vitamin D (16 microg/d) and calcium (700 mg/d) supplements. BMD was measured by using dual-energy X-ray absorptiometry. Concentrations of hormones and bone turnover markers were measured in serum. RESULTS: In men, no difference between groups occurred in any BMD measures or in bone turnover markers during year 1 or year 2. The free testosterone index and estradiol increased in the DHEA group only. In women, spine BMD increased by 1.7 +/- 0.6% (P = 0.0003) during year 1 and by 3.6 +/- 0.7% after 2 y of supplementation in the DHEA group; however, in the placebo group, spine BMD was unchanged during year 1 but increased to 2.6 +/- 0.9% above baseline during year 2 after the crossover to DHEA. Hip BMD did not change. Testosterone, estradiol, and insulin-like growth factor 1 increased in the DHEA group only. In both groups, serum concentrations of bone turnover markers decreased during year 1 and remained low during year 2, but did not differ between groups. CONCLUSION:DHEA supplementation in older women, but not in men, improves spine BMD when co-administered with vitamin D and calcium. This trial was registered at clinicaltrials.gov as NCT00182975.
Authors: Michal J Tracz; Kostandinos Sideras; Enrique R Boloña; Rudy M Haddad; Cassie C Kennedy; Maria V Uraga; Sean M Caples; Patricia J Erwin; Victor M Montori Journal: J Clin Endocrinol Metab Date: 2006-05-23 Impact factor: 5.958
Authors: K Sreekumaran Nair; Robert A Rizza; Peter O'Brien; Ketan Dhatariya; Kevin R Short; Ajay Nehra; Janet L Vittone; George G Klee; Ananda Basu; Rita Basu; Claudio Cobelli; Gianna Toffolo; Chiara Dalla Man; Donald J Tindall; L Joseph Melton; Glenn E Smith; Sundeep Khosla; Michael D Jensen Journal: N Engl J Med Date: 2006-10-19 Impact factor: 91.245
Authors: Richard Eastell; Rosemary A Hannon; Jack Cuzick; Mitch Dowsett; Glen Clack; Judith E Adams Journal: J Bone Miner Res Date: 2006-08 Impact factor: 6.741
Authors: Matti J Välimäki; Jordi Farrerons-Minguella; Johan Halse; Heikki Kröger; Marilyn Maroni; Henk Mulder; Manuel Muñoz-Torres; Maria Sääf; Erik Snorre Øfjord Journal: Clin Ther Date: 2007-09 Impact factor: 3.393
Authors: Krzysztof Rutkowski; Paweł Sowa; Joanna Rutkowska-Talipska; Anna Kuryliszyn-Moskal; Ryszard Rutkowski Journal: Drugs Date: 2014-07 Impact factor: 9.546
Authors: Catherine M Jankowski; Pamela Wolfe; Sarah J Schmiege; K Sreekumaran Nair; Sundeep Khosla; Michael Jensen; Denise von Muhlen; Gail A Laughlin; Donna Kritz-Silverstein; Jaclyn Bergstrom; Richele Bettencourt; Edward P Weiss; Dennis T Villareal; Wendy M Kohrt Journal: Clin Endocrinol (Oxf) Date: 2018-12-09 Impact factor: 3.478
Authors: Amy D Divasta; Henry A Feldman; Courtney Giancaterino; Clifford J Rosen; Meryl S Leboff; Catherine M Gordon Journal: Metabolism Date: 2012-01-16 Impact factor: 8.694
Authors: Dirk Vanderschueren; Michaël R Laurent; Frank Claessens; Evelien Gielen; Marie K Lagerquist; Liesbeth Vandenput; Anna E Börjesson; Claes Ohlsson Journal: Endocr Rev Date: 2014-09-09 Impact factor: 19.871